Press releases

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

Atriva Therapeutics Announces Changes to Management

Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

Aptamer Group, Mologic Ink Deal to Develop Coronavirus Antigen Test

LightOx: Developing new therapeutic solutions to improve patients function and long term outcomes with oral cancer

Atriva Therapeutics Announces Changes to Advisory Board

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Aptamer Group on BBC Look North 17th June 2020

LightOx May 2020

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

Therapieansätze gegen das Wuhan-Virus Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren

Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Britten kopen farmabedrijf Synthon uit Nijmegen

Dringend gezocht: nieuwe antibiotica